A Phase 1 interventional study of Nalmefene Hydrochloride and Nalmefene in Pharmacokinetics, sponsored by Opiant Pharmaceuticals Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-13.
Sponsored by Opiant Pharmaceuticals Inc (part of Indivior Pharmaceuticals, Inc.) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is to determine the pharmacokinetics (how the body absorbs, breaks down and eliminates drug from your body) of nalmefene when given intranasally (IN;into the nose) compared to a dose of nalmefene when given intramuscularly (IM; into the muscle); to compare the blood levels of nalmefene when given IN to nalmefene when given IM; and to evaluate the safety and tolerability of nalmefene IN.
Open-label, randomized, 2-period, 2-treatment, 2-sequence, crossover study in 68 healthy volunteers. Subjects will be assigned to each of the 2 possible sequences. Each subject will receive 2 treatments during the 2 dosing periods: Intranasal (IN) dose of 3 mg nalmefene hydrochloride and intramuscular (IM) dose of 1.0 mg nalmefene, with a 4 day washout period between doses. Screening can occur up to 28 days before baseline admission, subjects will then stay in the inpatient facility for 7 days to complete the treatment phase of the study and will be discharged following completion of the discharge procedures at the end of the last period. Subjects will be called 3 to 5 days after discharge to inquire concerning Adverse Events (AEs) and concomitant medications since discharge.
Opiant Pharmaceuticals Inc is the lead sponsor of 3 studies on the registry; none are open to participants now.
First submitted before Opiant Pharmaceuticals Inc became part of Indivior Pharmaceuticals, Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nalmefene hydrochloride nasal spray, 3mg, 1 spray
Drug: Nalmefene Hydrochloride
Nalmefene injection, 1mg, 1 injection
Drug: Nalmefene
3mg nasal spray
1mg intramuscular injection
Maximum Plasma Concentration (Cmax)
Maximum concentration of plasma nalmefene comparing IN to IM
Time frame: 48 hours
Time to Maximum Plasma Concentration (Tmax)
Time to maximum concentration of plasma nalmefene comparing IN to IM
Time frame: 48 hours
Area Under the Curve (AUC-inf)
Area under the curve of plasma nalmefene comparing IN to IM
Time frame: 48 hours
Half-life (t1/2)
Half life of plasma nalmefene comparing IN to IM
Time frame: 48 hours
Complete
| Milestone | Intranasal Nalmefene Then Intramuscular Nalmefene | Intramuscular Nalmefene Then Intranasal Nalmefene |
|---|---|---|
| Started | 34 | 34 |
| Completed | 34 | 34 |
| Not completed | 0 | 0 |
| Milestone | Intranasal Nalmefene Then Intramuscular Nalmefene | Intramuscular Nalmefene Then Intranasal Nalmefene |
|---|---|---|
| Started | 34 | 34 |
| Completed | 34 | 32 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Milestone | Intranasal Nalmefene Then Intramuscular Nalmefene | Intramuscular Nalmefene Then Intranasal Nalmefene |
|---|---|---|
| Started | 34 | 32 |
| Completed | 34 | 32 |
| Not completed | 0 | 0 |
Maximum concentration of plasma nalmefene comparing IN to IM
| ng/ml | Intranasal Nalmefene | Intramuscular Nalmefene |
|---|---|---|
| Maximum Plasma Concentration (Cmax) | 12.2 ± 6.71 | 1.77 ± 1.18 |
Time to maximum concentration of plasma nalmefene comparing IN to IM
| hours | Intranasal Nalmefene | Intramuscular Nalmefene |
|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) | 0.25 (0.0833 to 2) | 0.333 (0.117 to 18) |
Area under the curve of plasma nalmefene comparing IN to IM
| hour*ng/mL | Intranasal Nalmefene | Intramuscular Nalmefene |
|---|---|---|
| Area Under the Curve (AUC-inf) | 41.5 ± 8.45 | 17.0 ± 3.13 |
Half life of plasma nalmefene comparing IN to IM
| hour | Intranasal Nalmefene | Intramuscular Nalmefene |
|---|---|---|
| Half-life (t1/2) | 11.4 ± 2.37 | 10.6 ± 1.95 |
Collected over Subjects in the study from baseline to 7 days with a =3 to 5 day follow-up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intranasal Nalmefene | 0/66 (0%) | 0/66 (0%) | 42/66 (63.6%) |
| Intramuscular Nalmefene | 0/68 (0%) | 0/68 (0%) | 8/68 (11.8%) |
| Event | Intranasal Nalmefene | Intramuscular Nalmefene |
|---|---|---|
| nasal discomfortRespiratory, thoracic and mediastinal disorders | 37/66 | 0/68 |
| dizzinessNervous system disorders | 4/66 | 1/68 |
| headacheNervous system disorders | 3/66 | 4/68 |
| nauseaGastrointestinal disorders | 2/66 | 4/68 |
| Age, Customized(Participants) | Intranasal Nalmefene Then Intramuscular Nalmefene | Intramuscular Nalmefene Then Intranasal Nalmefene | Total |
|---|---|---|---|
| Age 18 to 55 years old | 34 | 34 | 68 |
| Sex: Female, Male(Participants) | Intranasal Nalmefene Then Intramuscular Nalmefene | Intramuscular Nalmefene Then Intranasal Nalmefene | Total |
|---|---|---|---|
| Female | 10 | 18 | 28 |
| Male | 24 | 16 | 40 |
| Race/Ethnicity, Customized(Participants) | Intranasal Nalmefene Then Intramuscular Nalmefene | Intramuscular Nalmefene Then Intranasal Nalmefene | Total |
|---|---|---|---|
| American Indian or Alaska native | 0 | 0 | 0 |
| Asian | 1 | 2 | 3 |
| Black or African American | 11 | 12 | 23 |
| Native Hawaiian or other specific islander | 1 | 0 | 1 |
| White | 21 | 20 | 41 |
| Multiple | 0 | 0 | 0 |
| Region of Enrollment(participants) | Intranasal Nalmefene Then Intramuscular Nalmefene | Intramuscular Nalmefene Then Intranasal Nalmefene | Total |
|---|---|---|---|
| United States | 34 | 34 | 68 |
| BMI(kg/m2) | Intranasal Nalmefene Then Intramuscular Nalmefene | Intramuscular Nalmefene Then Intranasal Nalmefene | Total |
|---|---|---|---|
| Mean | 26.58 ± 2.540 | 25.60 ± 2.996 | 26.09 ± 2.800 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in May 2021, 3 months.
Results were first posted in Aug 2024, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nalmefene